You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Analyzing the efficacy of MMP-13 inhibitors in the treatment of CIPN
SBC: Avantyx Pharmaceuticals, LLC Topic: 102Project Summary The goal of this project is to establish an effective drug candidate to treat chemotherapy-induced peripheral neuropathy (CIPN). The National Cancer Institute estimates that approximately 400,000 (or ~60-70%) of patients undergoing chemotherapy suffer from CIPN. These patients may need to terminate chemotherapy treatment if experiencing symptoms, such as numbness, pain, temperature ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
A new drug entity for combination therapy of diabetic retinopathy
SBC: EVERGLADES BIOPHARMA LLC Topic: NEIProject Summary Diabetic retinopathy (DR) is a leading cause of vision loss in working adults. A major breakthrough in DR therapy is the advent and approval of vascular endothelial growth factor (VEGF) inhibitors. However, anti-VEGF therapy has limited efficacy. The critical barrier is how to improve treatment efficacy in patients resistant to VEGF inhibitors. One of the strategies is to simultane ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Development of Notch1-selective Small Molecule Inhibitor for the Treatment of Cancer
SBC: Stemsynergy Therapeutic Topic: NCIABSTRACT The incidence of esophageal adenocarcinoma (EAC) has tripled over the last 40 years, but five-year overall survival is still poor due to late stage diagnosis, metastasis, and high rates of recurrence after standard chemotherapy. Standard-of-care therapy (neoadjuvant chemotherapy, radiation, or both followed by esophagectomy) achieves only 20% response rates, while 80% of patients remain p ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Advancing emergency medicine training with remote stereoscopic livestream technology
SBC: IMMERSIVE TECH INC Topic: 1001 Abstract: Immertec is facilitating more efficient dissemination of medical knowledge by creating2 a live immersive platform that allows remote physicians to feel as if they are in the same room3 from any location with access to timely biomedical feeds. Immertec has developed proprietary4 software for stereoscopic streaming video in virtual reality (VR), along with relevant biomedical5 feeds, tha ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Promoting adult hippocampal neurogenesis in Alzheimer's Disease using an antibody-based therapy
SBC: BOLDEN THERAPEUTICS, INC. Topic: RPROJECT SUMMARY Alzheimer's disease (AD) is a looming public health crisis that threatens millions of patients' ability to experience healthy aging. In addition to the challenges that AD poses to patients, healthcare providers and caregivers, there is also tremendous economic burden associated with AD and related dementias – estimated to be well over $200B/year in the United States alone. Hundre ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
A MULTIFACETED DIGITAL HEALTH PLATFORM TO ADVANCE ALZHEIMER'S DISEASE PATIENT MONITORING, SAFETY, CARE, AND RESEARCH.
SBC: AMISSA, INC. Topic: NIAProject Summary Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD) are projected to affect 50 million Americans by 2050. In 2019, more than 16 million Americans struggled while providing unpaid care for people with AD/ADRD and they need stigma-free solutions to help remotely monitor challenging AD/ADRD behaviors like falling and wandering. Separate but related, many AD/ADRD clinical trials ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Hesperos Diversity Supplement forgrant number 1 R44AG071386
SBC: HESPEROS, INC Topic: RProject Summary/AbstractThe burden associated with polypharmacy and inappropriate drug use is the third leading cause of death in the USA. With advanced age, providing medical care can present challenges as these patients are at risk for comorbidities and have the largest burden of illness. There is the unmet need of having proper approaches and innovative tools to identify not only drugs but also ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Epilepsy Seizure Detection with Innovative Tripolar EEG (tEEG)
SBC: CREMEDICAL CORP Topic: NINDSPROJECT SUMMARY Electroencephalography (EEG) is an essential component in the evaluation of epilepsy, the most common serious brain disorder worldwide. Misdiagnosis of epilepsy is very common and occurs in up to 50% of the patients. Artifact contamination seriously hinders the effectiveness of EEG and is a root cause of misdiagnosis. CREmedical is developing a tripolar concentric ring electrode (T ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
PP2A Anchoring Disruptor Therapy in Heart Failure
SBC: CARDIAC RSK3 INHIBITORS, LLC Topic: NHLBIPathological cardiac remodeling constitutes a common pathway to heart failure in disease. Despite current pharmacologic therapy and other advances that attenuate remodeling, morbidity and mortality due to heart failure remain high. Novel therapeutic approaches are desperately needed in an expanding patient population to improve both the survival and quality of life for patients with or susceptible ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Synthesis and screening of DNA-encoded Libraries of Non-Peptidic Macrocycles
SBC: DELUGE BIOTECHNOLOGIES INC Topic: 300Project Summary Most drugs target proteins with relatively deep pockets, such as enzyme active sites. However, screening collections comprised of these traditional Rule of 5-compliant molecules have consistently failed to provide high quality drug leads for many targets that function via protein-nucleic acid and protein-protein interactions (PPIs). These are the “difficult” or “undruggable ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health